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{1}  Good afternoon ladies and gentlemen.  I have an enormous opportunity and challenge.  Here I 
am, the final speaker, on this final panel, on this beautiful Friday afternoon, on this beautiful campus.  
Stay “tuned” for just a few more minutes to hear my remarks regarding liability issues and then we 
will adjourn to the great outdoors.
{2}  Drew Kershen’s earlier presentation reminded me that issues related to genetically modified foods 
are issues that can generate great passion.  More generally, I have seen many different perspectives 
presented today by different speakers.  Each speaker has made a unique and valuable contribution to 
this program and has helped all of us understand biotechnology in a more complete way.  I hope I can 
follow suit.  
{3}  Let me turn to the topic of civil liability issues related to agricultural biotechnology.  I will 
examine civil liability in the context of the StarLink incident, an incident that has been alluded to 
on several occasions earlier today.  To refresh your memories, StarLink was an incident in which a 
particular genetically engineered corn variety – StarLink™ – was approved by the EPA for animal 
feed use only.  This “split” approval (approval for feed but not food use) occurred in 1999, but the 
larger planting of StarLink seed was in year 2000.  The discovery of trace amounts of StarLink corn in 
taco shells and other foods confirmed that StarLink had inadvertently moved from feed channels into 
food channels, even though it was not yet approved for food use.  Thus, any food containing StarLink 
was, in fact, “adulterated” as the term is defined in the Federal Food, Drug, and Cosmetic Act.  Foods 
containing StarLink were recalled from grocery store shelves.  StarLink seed was also taken off the 
market.  The whole incident raised issues of who is liable for what.1
I. The StarLink incident teaches us that the costs of civil liability can be very high.
{4}  When we look at the StarLink incident, we can make one general point: if, in spite of a rigorous 
regulatory system, something does go wrong with a biotech product – perhaps people experience an 
allergic reaction or, as in the StarLink case, perhaps some people experience economic damage – then 
the costs of civil liability can be incredibly high.  
{5}  For example, Aventis, the company that “owned” StarLink, first incurred significant costs in 
purging StarLink from food and export channels.  Millions of dollars were expended by Aventis in an 
effort to get this product back into “feed only” uses after it moved inadvertently into food and export 
channels.  And this cost was only the beginning.  
{6}  There also was a settlement of consumer class action lawsuits where consumers alleged that they 
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suffered allergic reactions.  The cost of that settlement was about nine million dollars, a second cost 
arising because Aventis made the mistake of allowing this product to move into food channels where it 
was not yet approved.2  Interestingly, the nine million dollar cost of settling this consumer Class Action 
lawsuit occurred without any conclusive evidence that any allergic reactions to StarLink’s novel protein 
had, in fact, taken place.  We still haven’t established whether StarLink’s Cry9C protein is or is not an 
allergen.  It has never been proven not to be an allergen because that is a very, very difficult thing to 
prove.
{7}  But the Starlink-related libility doesn’t end there.  As we speak, farmers across the corn belt are 
deciding whether they should opt out of another Class Action lawsuit, this one brought by non-StarLink 
corn producers.  Farmers must make a decision by March 21, 2003 – within a week – about whether to 
opt out.  Each farmer that remains in the class will submit a claim for his or her respective share of a 
$110 million proposed settlement of this Class Action lawsuit.3  By the way, that’s not “big bucks” for 
individual corn producers.  I worked through some numbers.  It’s about a dollar or two an acre for every 
acre of non-Star Link corn harvested for grain in the year 2000.
{8}  But liability may not end there, either.  What settlements will be made with food retailers regarding 
food recalls?  What settlements will be made with other companies for rejected food shipments?  Any 
such settlements are unlikely to be very public.  But undoubtedly the food recalls create liability issues 
as well.
{9}  My first general point is this.  The StarLink incident teaches us that if a company makes a mistake 
in commercializing a transgenic crop, the cost of civil liability for food biotechnology can be very high.  
In the case of StarLink, it included the costs of destroying the remaining seed inventory, locating and 
removing from the U.S. corn supply StarLink corn and corn commingled with StarLink, settling with 
consumers who allegedly suffered allergic reactions (although no such reactions were proven), settling 
a class action lawsuit by corn growers who allegedly suffered depressed corn prices as a result of the 
mistake, and probably settling other claims for damages arising from food recalls and rejected food 
shipments.
II. The StarLink incident illustrates that many legal theories may support liability claims.
{10}  My second point is that there are, in fact, many legal theories that potentially support liability 
claims if there is, in fact, damage resulting from genetically engineered products.  For example, if we 
look at the Non-StarLink Farmers Class Action lawsuit, on July 11, 2002, Judge Moran ruled upon a 
Motion to Dismiss.4  In that Motion we see that negligence, negligence per se, strict liability in tort, 
trespass, private nuisance, public nuisances, and others are all theories under which the company which 
markets a product might be liable for damage that would result.  There is no shortage of potential 
theories.
{11}  Most importantly, Judge Moran dealt with the economic loss doctrine.5  This is a doctrine that 
arguably could limit the responsibility of Aventis or Aventis’ successors for the economic damage that 
resulted.  This is the very kind of damage that the non-StarLink farmers were alleging, namely that the 
whole StarLink incident caused plaintiffs’ crop to become contaminated and caused a depressing effect 
on corn prices, and every corn farmer who sold any corn that year was in fact damaged because of 
depressed prices.  The economic loss doctrine might well preclude such recovery, but in his analysis of 
briefs on that issue, Judge Moran concluded that the economic loss doctrine, in the setting of StarLink, 
does not necessarily bar the Plaintiffs’ claims, and there should be an opportunity to offer proof on 
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various issues, including whether plaintiffs suffered direct harm, if the case proceeds to trail.
III. StarLink has sensitized the agriculture/food biotech chain to issues of liability.
{12}  Liability risks are clearly an important part of any decision by a biotech company to 
commercialize a transgenic product.  Thus, the liability regime is a complement to our regulatory 
system.  It is not just regulatory approval or lack of approval that will determine whether a product 
can go to market.  Separate and apart from the regulatory approval of the product, there will be an 
assessment by the company of any civil liability risk, and the company will weigh the potential profits 
of marketing that product against that liability risk.  The liability risk is a significant influence on the 
decision to commercialize a product and helps assure us that only safe products come to market.
IV. Should a special liability regime be created for biotechnology?
{13}  One of the policy questions surrounding biotechnology is whether claims for damages allegedly 
arising from the use of biotechnology products should be determined under existing principles 
of liability, or whether an alternative liability regime should be created.  In 1994, Dan Burk and 
Barbara Boczar outlined one proposal for a comprehensive biotechnology products liability scheme.6  
Under their proposal a special, no-fault liability scheme would apply to all products (a) produced 
through specified biotechnology techniques and (b) approved for use by a regulatory agency.  Also, 
compensation would be limited to the costs of medical care, death benefits, lost earnings, and pain 
and suffering (there would be caps on pain and suffering awards and no punitive damages would be 
allowed).
{14}  As a practical matter, no such alternative biotechnology liability scheme has been adopted for the 
United States to date.  For now, the U.S. appears to be content with biotech-related liability issues being 
resolved within the general tort liability scheme, based on theories previously noted.
V. Special liability issues where products are unapproved in major export markets.
{15}  The EPA has stated that it will not grant any more “split” approvals like we saw in the StarLink 
case where the genetically engineered corn was approved for feed but not food uses  However, we do 
have an analogous situation when some products are fully approved in the United States, but are not 
approved overseas.  What if farmers grow these products on a large scale in the United States and these 
crops “spillover” into export channels, e.g., shipments to the European Union where many biotech crops 
are not yet approved because of the de facto moratorium on new approvals?  In such a situation there is 
the potential for the export shipments to be either substantially discounted or even rejected and we have 
potential for economic loss.
{16}  Some of what we’ve learned in the StarLink liability litigation is probably applicable to this 
situation.  And it’s especially relevant since there is a new product coming out on the market this spring 
– a corn variety known as YieldGuard Rootworm™ – that has been genetically engineered to protect 
it from corn rootworm, a terribly devastating pest which has adapted so that our normal corn/soybean 
rotation doesn’t disrupt its life cycle anymore.7  Corn farmers are now using substantial amounts of 
pesticides to control this pest, since they can no longer control it with crop rotations.  Suffice it to say, 
YieldGuard Rootworm™  is expected to be a popular product with farmers.  It’s going to be grown 
in areas like my home state, Illinois, which also produces a lot of the grain for export because of our 
proximity to the river transportation system.  
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{17}  There is a great deal of concern among farmers.  Their concern is not about the safety of the 
product in a health sense, nor are farmers concerned about potential damages to the environment 
(farmers believe it is going to be very positive in that regard; it will replace pesticides that are viewed as 
being more problematic).  Their concern is about the potential negative impact of genetically engineered 
rootworm resistant corn on their export markets.
VI. Summary
{18}  We’ve learned much about liability from the StarLink incident: 
• The cost of civil liability for food biotech can be very high if a company makes a mistake in 
bringing a biotech product to market.  
• There are numerous legal theories that may support liability claims in the right set of 
circumstances (and there is no apparent movement to create a special “no-fault” liability system 
for the products of biotechnology).  
• The potential for liability is incorporated into a company decision to move forward in marketing 
a product; thus the liability regime complements the biotech regulatory regime in helping to 
assure that products coming to market are safe.
• The potential for commingling and the resulting “economic loss” that arose from EPA’s “split” 
approval of StarLink is also present when a genetically engineered crop is fully approved in the 
U.S. but is not approved in major export markets.  
{19}  In addition, there are many liability-related issues to be resolved in the future.  For example, 
throughout the food chain, who has what responsibility to prevent the inadvertent mixing of approved- 
and unapproved-for-export grain?  Who has what responsibility to test, and with what protocols?  Who 
can be indemnified through contract language, and when do these liability-shifting contracts violate 
public policy?  Could the potential release of a fully approved variety in the United States be enjoined 
through court action because the release in the U.S. of an “unapproved-in-export markets” variety might 
constitute a public nuisance.  This issue has been discussed in the past with the result that a biotech 
company chose to voluntarily withhold its product from market until additional overseas approvals 
could be forthcoming.8
{20}  The liability issues related to agricultural biotechnology are intriguing.  They are exciting for the 
Plaintiff’s bar, for the Defendant’s bar, for policymakers, for consumers, and for all of us.  
____________________________________________________________________________________________________
* Donald Uchtmann is a professor at the University of Illinois at Urbana-Champaign where he teaches classes 
on Agriculture Law and Rural Taxation.  His research focuses on the evolving law of biotechnology and 
issues in water and natural resources law.  His more general interests include legal issues in grain marketing, 
and agricultural taxation and law.  From 1981-1982, he served as President of the American Agricultural Law 
Association, and while on sabbatical leave during 2002, he was a visiting scholar with the Pew Initiative on Food 
and Biotechnology in Washington, D.C.  Mr. Uchtmann has published two textbooks and numerous refereed 
articles, and he has presented papers, conducted research, or served as a consultant in many countries, including 
Brazil, Great Britain, France, Italy, Poland, Russia, Kazakhstan, China, and Japan.  He received his B.S. degree 
with honors in Agricultural Science from the University of Illinois, and earned his M.A. at the University of 
Leeds, England, where he studied economic development.  He earned his J.D., cum laude, from The Cleveland 
State University.
1 See D. L. Uchtmann, StarLink™ -- A Case Study of Agricultural Biotechnology Regulation, 7 DRAKE J. AGRIC. 
LAW, 159, 174-202 (2002).
 
Richmond Journal of Law & Technology- Winter 2004- Volume X, Issue 2
Food Biotechnology: A Legal Perspective- Donald Uchtmann
2 Jill Carroll, Judge Will Approve Settlement on Use of StarLink Corn, WALL ST. J., Mar. 7, 2002, at A4.
3 See In re StarLink Corn Products Liability Litigation, 152 F. Supp. 2d 1378 (J.P.M.L. 2001)
4 In re StarLink Corn Products Liability Litigation, 212 F. Supp. 2d 828 (N.D. Ill. 2002).
5 Id. at 838. 
6 See Dan L. Burk & Barbara A. Boczar, Biotechnology and Tort Liability, A Strategic Industry at Risk, 55 U. 
PITT L. REV. 791, 794 (1994).  The authors argue that the traditional tort liability system doesn’t serve the public 
interest well because many issues will require expert scientific testimony and such issues tend to bring out the 
worst in the American tort liability system.  The authors also argue that, absent a special liability system, the costs 
of liability will make the biotech industry uncompetitive internationally.  Id. at 794.
7 The trade name for the product is YieldGard Rootworm™.  See EPA, Fact Sheet (EPA Publication Number: 
730-F-03-01) for Bacillus thuringiensis Cry3Bb1 Protein and the Genetic Material Necessary for its Production 
(Vector ZMIR13L) in Event MON863 Corn (March 6, 2003), available at http://www.epa.gov/oppbppd1/
biopesticides/ingredients/factsheets/factsheet_006484.htm (last visited Jan. 7, 2004).
8 Thomas P. Redick, Biopharming, Biosafety, and Billion Dollar Debacles:  Preventing Liability for Biotech 
Crops, 8 DRAKE J. AGRIC. LAW 115, 136-37 (2003).
